Table 4 Characteristics of quality of life values used
From: Cost-effectiveness of prostate cancer screening: a systematic review of decision-analytical models
Study | Study setting | Perspective | Assessment of QoL | Population | Country |
|---|---|---|---|---|---|
Chilcott et al. [23] | UK | NHS | HUI/EQ-5D | General population | UK/other |
Heijnsdijk et al. [25] | NR | Healthcare based on included costs | SG/EQ-5D/TTO/VAS | Patients/experts/ general population | Netherlands, US, Canada |
Hummel and Chilcott [24] | UK | NHS | HUI/EQ-5D | General population | UK/other |
Keller et al. [29] | Australia | Healthcare | SF-12/ SF-36/ othera, b | General population | Australia/ Finland |
Kobayashi et al. [27] | NR | Societal | TTO | Physicians/ patients | Unclear |
Martin et al. [30] | Australia | Healthcare | SF-12/ SG | Patient/ General population | US (adjusted)/ Australia |
Pataky et al. [26] | Canada | Healthcare based on included costs | SG | 2 different patient groups | Canada |
Roth et al. [28] | US | US payer perspective | SG | Patient | US |